Why the study?
Assessing atrial fibrotic substrates is essential for guiding treatment and predicting catheter ablation success in AF, but substrate evaluation remains complex.
Key points are not available for this paper at this time.
Design
Clinical review
Answers are grounded in this paper and cite their sources.
This review summarizes current knowledge on the pathophysiology, diagnosis, and management of atrial fibrotic substrates in atrial fibrillation.
Atrial fibrillation (AF) is the most common sustained arrhythmia in the population and is associated with a significant clinical and economic burden. Rigorous assessment of the presence and degree of an atrial arrhythmic substrate is essential for determining treatment options, predicting long-term success after catheter ablation, and as a substrate critical in the pathophysiology of atrial thrombogenesis. Catheter ablation of AF has developed into an essential rhythm-control strategy. Nowadays is one of the most common cardiac ablation procedures performed worldwide, with its success inversely related to the extent of atrial structural disease. Although atrial substrate evaluation remains complex, several diagnostic resources allow for a more comprehensive assessment and quantification of the extent of left atrial structural remodeling and the presence of atrial fibrosis. In this review, we summarize the current knowledge on the pathophysiology, etiology, and electrophysiological aspects of atrial substrates promoting the development of AF. We also describe the risk factors for its development and how to diagnose its presence using imaging, electrocardiograms, and electroanatomic voltage mapping. Finally, we discuss recent data regarding fibrosis biomarkers that could help diagnose atrial fibrotic substrates.
No takes yet. Share an insight, caveat, or question.
Cunha et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: